Classification of current anticancer immunotherapies
Lorenzo Galluzzi(Délégation Paris 5), Enrico Lugli(National Institutes of Health), Guido Kroemer(Inserm), Klas Kärre(Karolinska Institutet), Dirk Jäger(German Cancer Research Center), John M. Kirkwood(UPMC Hillman Cancer Center), Jean-Pierre Abastado(Singapore Immunology Network), Giuseppe Giaccone(Georgetown University), Michael T. Lotze(UPMC Hillman Cancer Center), Laura Bracci(Istituto Superiore di Sanità), Lisa M. Coussens(Oregon Health & Science University), Roland Liblau(Inserm), Rolf Kiessling(Karolinska University Hospital), Erika Vacchelli(Inserm), Dmitry I. Gabrilovich(University of South Florida), Jean‐Yves Blay(Centre Léon Bérard), François Ghiringhelli(Inserm), Anne Hosmalin(Université Paris Cité), Jitka Fučíková(Charles University), Claire E. Lewis(University of Sheffield), Oliver Kepp(Inserm), Paweł Kaliński(Roswell Park Comprehensive Cancer Center), Abhishek D. Garg(KU Leuven), Chiara Castelli(Fondazione IRCCS Istituto Nazionale dei Tumori), Eli Gilboa(University of Miami), Jérôme Galon(Inserm), Elisa Elena Baracco(Inserm), Philipp Beckhove(University Hospital Regensburg), Laura Senovilla(Inserm), Wolf H. Fridman(Centre de Recherche des Cordeliers), Anne Caignard(Inserm), Sacha Gnjatic(Mount Sinai Hospital), Ron N. Apte(Ben-Gurion University of the Negev), Maha Ayyoub(Inserm), Mario P. Colombo(University of Palermo), Douglas T. Fearon(Cornell University), Axel Hoos(GlaxoSmithKline (United States)), Aled Clayton(Cardiff University), José Manuel Bravo‐San Pedro(Inserm), Fernando Aranda(Inserm), Madhav V. Dhodapkar(Emory University), Norma Bloy(Université Paris-Sud), Patrizia Agostinis(VIB-KU Leuven Center for Cancer Biology), Alexander Eggermont(University Medical Center Utrecht), Francesca Castoldi(Inserm), Alexander Knuth(National Center for Cancer Care and Research), Eva Klein(Karolinska Institutet), Vincenzo Cerundolo(University of Oxford), Estaban Celis(Augusta University), Federica Cavallo(University of Turin), Aitziber Buqué(Inserm)
Cited by 469
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.4k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Photodynamic therapy of cancer: An update
|CA A Cancer Journal for Clinicians|2011|5.1k